Want to see TSE:HBP full AI Analyst Report?
HBP Stock Chart & Stats
C$1.42
-C$0.01(-0.70%)
At close: 4:00 PM EDT
C$1.42
-C$0.01(-0.70%)
Day’s Range― - ―
52-Week RangeC$1.10 - C$5.40
Previous CloseN/A
Volume206.00
Average Volume (3M)13.00K
Market Cap
C$150.46M
Enterprise ValueC$111.32M
Total Cash (Recent Filing)C$2.84M
Total Debt (Recent Filing)C$359.00K
Price to Earnings (P/E)―
Beta2.38
Next Earnings
Nov 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding76,378,100
10 Day Avg. Volume29,165
30 Day Avg. Volume13,000
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)3.83
Price to Sales (P/S)0.00
P/FCF Ratio-15.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageVery low debt relative to equity limits solvency pressure and reduces the risk that interest or principal obligations constrain research spending. This gives Helix greater financial flexibility than a similarly loss-making biotech with substantial leverage.
Balance Sheet TurnaroundThe move from negative to positive equity indicates a meaningful improvement in financial stability, likely supported by recapitalization or other balance-sheet changes. A stronger capital base can help sustain development activities and improve resilience over the next several quarters.
Narrowing Losses And BurnAlthough the company remains unprofitable, the improvement in reported losses and historical cash burn suggests some progress toward cost control. If maintained, this trend could extend its funding runway and reduce the pace at which additional capital is required.
Bears Say
No Commercial RevenueHelix has no operating revenue base to absorb fixed costs or internally fund its oncology programs. Until a candidate is commercialized or partnered, the business remains dependent on clinical progress and external financing rather than recurring customer demand.
Persistent Operating LossesPersistent losses indicate that development expenses currently exceed any available income, leaving earnings quality structurally weak. Without revenue or a successful program milestone, continued deficits may limit strategic flexibility and increase reliance on future capital raises.
Negative Cash GenerationNegative operating and free cash flow means the company is consuming cash rather than financing development internally. The recent re-acceleration of outflows further raises the risk that additional financing will be needed before programs can generate meaningful economic returns.
Helix BioPharma News
HBP FAQ
What was Helix BioPharma’s price range in the past 12 months?
Helix BioPharma lowest stock price was C$1.10 and its highest was C$5.40 in the past 12 months.
What is Helix BioPharma’s market cap?
Helix BioPharma’s market cap is C$150.46M.
When is Helix BioPharma’s upcoming earnings report date?
Helix BioPharma’s upcoming earnings report date is Nov 04, 2026 which is in 73 days.
How were Helix BioPharma’s earnings last quarter?
Helix BioPharma released its earnings results on Jun 10, 2026. The company reported -C$0.009 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.009.
Is Helix BioPharma overvalued?
According to Wall Street analysts Helix BioPharma’s price is currently Overvalued.
Does Helix BioPharma pay dividends?
Helix BioPharma does not currently pay dividends.
What is Helix BioPharma’s EPS estimate?
Helix BioPharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Helix BioPharma have?
Helix BioPharma has 76,378,100 shares outstanding.
What happened to Helix BioPharma’s price movement after its last earnings report?
Helix BioPharma reported an EPS of -C$0.009 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.947%.
Which hedge fund is a major shareholder of Helix BioPharma?
Currently, no hedge funds are holding shares in TSE:HBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Helix BioPharma
Based in Richmond Hill, Canada, Helix BioPharma Corp. is a Canadian immune-oncology company focused on therapeutic development. The firm is progressing L-DOS47 for treating non-small cell lung cancer and is also working on V-DOS47, which targets the vascular epithelial growth factor receptor 2. Helix BioPharma has formed strategic alliances, including one with Moffitt Cancer Center to analyze L-DOS47's pharmacodynamics and assess the benefits of integrating it with immune checkpoint inhibitors. Another partnership, with ProMab Biotechnologies, Inc., is dedicated to creating innovative antibody and chimeric antigen receptor T-cell therapies to combat multiple myeloma. Furthermore, the company maintains licensing agreements with Xisle Pharma Ventures Trust and the National Research Council Canada.
Technical Analysis
Satellos Bioscience
―
Arch Biopartners
―
Medicenna Therapeutics Corp
―
ME Therapeutics Holdings, Inc.
―
Onco-Innovations Ltd.
―